In a blog, the facility writes that MT2 isn't "currently approved by the FDA." Additionally, West Lake Dermatology says that the compound "cannot be legally marketed or sold as a drug, supplement, or cosmetic product." Further, it isn't "used in standard medical practices." It's "largely unregulated, with no reliable assurance of purity, sterility, or dosing." West Lake Dermatology writes that MT2 began its life as a peptide used for academic purposes
Emerging agents like Tirzepatide, which activates both GLP-1 and GIP receptors, and Orforglipron, a nonpeptide oral GLP-1 agonist in phase 2 trials, further expand the therapeutic potential of this class (23)(24)
This combination works through complementary pathways that enhance nitric oxide (NO) production, bioavailability, and stability -- delivering benefits that exceed simple addition of their individual effects
Post Hepatectomy Liver Failure - A Comprehensive Review of Current Concepts and Controversies